Clinical trial · Interventional
Cerebral Oxygenation and Metabolism After Reversal Of Rocuronium: Comparison Between Sugammadex Versus Neostigmine
Cerebral Oxygenation and Metabolism After Reversal Of Rocuronium Neuromuscular Blockade In Cases Of Supratentorial Tumors: A Comparative Study Between Sugammadex Versus Neostigmine
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cholinesterase inhibitors such as Neostigmine and Edrophonium have been used to reverse neuromuscular blockade after surgery. However, these drugs have a relatively slow onset and have adverse effects associated with stimulation of muscarinic receptors. In addition, neostigmine cannot be used to reverse profound blockade. Anesthetics may exert their effects on various facets of cerebral function such as cerebral metabolic rate (CMRO2), cerebral blood flow (CBF), cerebral blood flow-metabolism coupling, intra cranial pressure (ICP), autoregulation, vascular response to CO2 and brain electrical activity. The net result of all these effects of the anaesthetic agents combined with their systemic effects may prove beneficial or detrimental to an already diseased brain. In neurosurgical patients, clear and rapid recovery is required to early assess the neurological status and to maintain the cerebral oxygenation and metabolism within the normal physiological values which may be saved by sugammadex.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Supratentorial Brain Tumor Surgery | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Neostigmine | Drug | — | UNRESOLVED |
| Sugammadex | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Sugammadex
- description
- Patients will receive Sugammadex to antagonise the residual effects of neuromuscular blocking drugs
- interventionNames
- Drug: Sugammadex
- type
- ACTIVE_COMPARATOR
- label
- Neostigmine
- description
- Patients will receive Neostigmine to antagonise the residual effects of neuromuscular blocking drugs
- interventionNames
- Drug: Neostigmine
Primary outcomes (1)
- measure
- Time to recovery of the train-of-four (TOF) ratio to 0.9
- timeFrame
- For 1 hour after surgery
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * American Society of Anesthesiologists physical class status I - III . * Patients scheduled for elective supratentorial brain tumor resection Exclusion Criteria: * Severe uncompensated cardiac disease. * Severe uncompensated respiratory disease. * Severe uncompensated hepatic disease. * Severe uncompensated renal disease. * Morbidly obese patients. * Documented hypersensitivity to one of the used drugs. * Surgery in sitting position * Surgery in prone position * Patients with altered level of consciousness. * Pregnancy.
References
Publications (0)
Data not yet available